Sanofi company profile
Company profile
Sanofi has 74,846 employees and is headquartered in Paris, France.
Employing 74,846 people, Sanofi researches, develops, manufactures and markets therapeutic solutions, with a focus on immunology and inflammation, rare diseases, neurology, oncology and vaccines. Its vaccine range includes pediatric vaccines against polio, pertussis and Hib, a hexavalent combination vaccine, protection against respiratory syncytial virus and the Fluzone flu vaccine. Dupixent, developed with Regeneron for diseases driven by type 2 inflammation, is one of its products. Partnerships with companies such as Teva, Kymera Therapeutics and Denali Therapeutics extend its pipeline into areas including ulcerative colitis and genome editing. By region, the US accounts for 50.8% of revenue, other countries for 28.2% and Europe for 21.0%.
Sanofi reported revenue of EUR 46.7 billion in the fiscal year ended December 2025, up 5.5% from the previous year, and net income of EUR 7.8 billion for the same period. The company was incorporated in 1994 as Sanofi-Aventis, changed its name to Sanofi in May 2011 and is headquartered in Paris, France. Its shares also trade on NASDAQ.
Company facts
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- France
- Headquarters
- 46, avenue de la Grande ArmEe, 75017, Paris
- Employees
- 74,846
- Chief executive
- Belen Garijo Lopez
- Founded
- 1994
- Fiscal year
- January - December
- Listing
- SAN · Euronext Paris
- Indices
- CAC 40
- Currency
- EUR
- ISIN
- FR0000120578
- Website
- sanofi.com
Sanofi and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| SanofiSAN | France | $116.52B | 74,846 | 22.3% | 25.5 |
| GSKGSK | United Kingdom | $102.04B | 66,841 | 30.5% | 18.0 |
| Novo NordiskNOVO.B | Denmark | $184.87B | 68,794 | 50.8% | 11.2 |
| BayerBAYN | Germany | $61.54B | 87,775 | 16.5% | — |
| AstraZenecaAZN | United Kingdom | $287.12B | 96,100 | 25.8% | 26.6 |
| NovartisNOVN | Switzerland | $305.16B | 75,267 | 34.0% | 32.6 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
